Feed Top Reports Pricing

⌘K

16:15:43·8d

SECFiling

SEC Form DEF 14A filed by Neurocrine Biosciences Inc.

NBIX· Neurocrine Biosciences Inc.

Health Care

Original source

Companies

NBIX
Neurocrine Biosciences Inc.
Health Care

Recent analyst ratings

Feb 24UpdateWolfe Research$160.00
Jan 8UpdateMorgan Stanley$175.00
Oct 21UpdateCitigroup$175.00
Jul 21UpdateTruist$163.00
Jul 10UpdateGoldman$182.00
Apr 15UpdateNeedham$138.00

Related

PR1d
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
SEC8d
SEC Form DEFA14A filed by Neurocrine Biosciences Inc.
PR9d
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
PR10d
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
SEC18d
Neurocrine Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
PR18d
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.
PR29d
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022